The GlaxoSmithKline plc (GSK) Earns “Hold” Rating from Deutsche Bank AG

The GlaxoSmithKline plc (GSK) Earns “Hold” Rating from Deutsche Bank AG

Other equities analysts have also issued reports about the company. Goldman Sachs Group Inc upped their target price on GlaxoSmithKline plc from GBX 1,800 ($23.12) to GBX 1,850 ($23.76) and gave the company a buy rating in a research note on Tuesday, January 24th. Liberum Capital restated a buy rating and set a GBX 1,900 ($24.41) price target on shares of GlaxoSmithKline plc in a research note on Tuesday, January 31st. HSBC Holdings plc restated a buy rating and set a GBX 1,970 ($25.31) price target on shares of GlaxoSmithKline plc in a research note on Thursday, February 9th. Beaufort Securities restated a buy rating and set a GBX 1,750 ($22.48) price target on shares of GlaxoSmithKline plc in a research note on Friday, February 10th. Finally, Jefferies Group LLC restated a buy rating and set a GBX 1,780 ($22.86) price target on shares of GlaxoSmithKline plc in a research note on Monday, February 13th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of GBX 1,751.77 ($22.50).

Deutsche Bank AG reiterated their hold rating on shares of GlaxoSmithKline plc (LON:GSK) in a research note issued to investors on Tuesday, May 23rd.

Shares of GlaxoSmithKline plc (LON GSK) opened at 1694.525 on Tuesday. The stock’s 50 day moving average is GBX 1,620.99 and its 200-day moving average is GBX 1,592.49. GlaxoSmithKline plc has a 52 week low of GBX 1,363.00 and a 52 week high of GBX 1,745.56. The stock’s market capitalization is GBX 82.79 billion. The firm also recently announced a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 11th will be given a GBX 19 ($0.24) dividend. This represents a yield of 1.21%. The ex-dividend date is Thursday, May 11th.

In other GlaxoSmithKline plc news, insider Vivienne Cox bought 335 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average cost of GBX 1,583 ($20.33) per share, for a total transaction of £5,303.05 ($6,811.88). Also, insider Dominic Redfern purchased 230 shares of the stock in a transaction dated Thursday, April 13th. The shares were purchased at an average price of GBX 1,639 ($21.05) per share, for a total transaction of £3,769.70 ($4,842.26). Over the last 90 days, insiders purchased 718 shares of company stock worth $1,183,024. About GlaxoSmithKline plc

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:GSK”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment